Comparative Pharmacology
Head-to-head clinical analysis: QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE versus UNIRETIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE versus UNIRETIC.
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE vs UNIRETIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Quinapril is an ACE inhibitor that inhibits the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion; hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, increasing excretion of sodium and water.
Uniretic is a combination of an angiotensin-converting enzyme (ACE) inhibitor (moexipril) and a thiazide diuretic (hydrochlorothiazide). Moexipril inhibits ACE, preventing conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Hydrochlorothiazide inhibits sodium reabsorption in distal convoluted tubule, increasing excretion of sodium and water.
Initial: 10/12.5 mg (quinapril/hydrochlorothiazide) orally once daily. Titrate based on response to a maximum of 40/25 mg once daily.
1-2 tablets (each containing hydrochlorothiazide 25 mg and spironolactone 25 mg) orally once daily. Maximum dose: 4 tablets/day.
None Documented
None Documented
Quinaprilat terminal half-life ~25 hours (effective half-life ~12 hours); hydrochlorothiazide ~6-15 hours (increased in renal impairment).
Terminal elimination half-life 13-17 hours; clinical context: supports once-daily dosing
Renal excretion of quinaprilat (active metabolite) ~50-60% unchanged; hydrochlorothiazide ~70% unchanged. Biliary/fecal elimination accounts for <10% for both components.
Renal: 50-70% unchanged; biliary/fecal: 10-15% as metabolites
Category D/X
Category C
ACE Inhibitor
ACE Inhibitor and Diuretic